Document Detail

Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure.
MedLine Citation:
PMID:  11304508     Owner:  NLM     Status:  MEDLINE    
Dendroaspis natriuretic peptide (DNP), a recently discovered peptide, shares structural similarity to the other known natriuretic peptides, ANP, BNP, and CNP. Studies have reported that DNP is present in human and canine plasma and atrial myocardium and increased in plasma of humans with congestive heart failure (CHF). In addition, synthetic DNP is markedly natriuretic and diuretic and is a potent activator of cGMP in normal animals. To date, the ability of synthetic DNP to improve cardiorenal function in experimental CHF is unknown. Synthetic DNP was administered intravenously at 10 and 50 ng. kg(-1). min(-1) in dogs (n=7) with severe CHF induced by rapid ventricular pacing for 10 days at 245 bpm. In addition, we determined endogenous DNP in normal (n=4) and failing (n=4) canine atrial and ventricular myocardium. We report that administration of synthetic DNP in experimental severe CHF has beneficial cardiovascular, renal, and humoral properties. First, DNP in CHF decreased cardiac filling pressures, specifically right atrial pressure and pulmonary capillary wedge pressure. Second, DNP increased glomerular filtration rate in association with natriuresis and diuresis despite a reduction in mean arterial pressure. Third, DNP increased plasma and urinary cGMP and suppressed plasma renin activity. Fourth and finally, we report that DNP immunoreactivity is present in canine atrial and ventricular myocardium and increased in CHF. These studies report the acute intravenous actions of synthetic DNP in experimental severe CHF and suggest that on the basis of its beneficial properties, DNP may have potential as a new intravenous agent for the treatment of decompensated CHF.
O Lisy; J G Lainchbury; H Leskinen; J C Burnett
Related Documents :
2144948 - Atrial natriuretic factor as a vasodilator agent in hypertensive patients.
2949908 - Relationship between the renin-aldosterone system and atrial natriuretic polypeptide in...
8296708 - Interaction of intravenous atrial natriuretic factor with furosemide in patients with h...
2528918 - Doca administration and atrial natriuretic factor in dogs with chronic heart failure.
16208138 - Prevalence and determinants of blood pressure screening in pakistan.
17238188 - Effect of a sustained inflation on regional distribution of gas and perfluorocarbon dur...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Hypertension     Volume:  37     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2001 Apr 
Date Detail:
Created Date:  2001-04-17     Completed Date:  2001-05-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1089-94     Citation Subset:  IM    
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Departments of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Blood Pressure / physiology
Cardiovascular Agents / metabolism,  therapeutic use*
Cyclic GMP / blood
Elapid Venoms / metabolism,  therapeutic use*
Glomerular Filtration Rate / drug effects
Heart Failure / drug therapy*,  metabolism,  physiopathology
Kidney Tubules / physiology
Myocardium / metabolism
Peptides / metabolism,  therapeutic use*
Pulmonary Wedge Pressure / physiology
Renin / blood
Reg. No./Substance:
0/Cardiovascular Agents; 0/Dendroaspis natriuretic peptide; 0/Elapid Venoms; 0/Peptides; 7665-99-8/Cyclic GMP; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Silent ST depression and cardiovascular end-organ damage in newly found, older hypertensives.
Next Document:  Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth.